Felipe Samaniego

TL;DR: Rituximab plus hyper-CVAD alternating with rituxIMab plus high-dose methotrexate and cytarabine is effective in untreated aggressive MCL and toxicity is significant but expected.

TL;DR: The combination of pidilizumab and rituximab was well tolerated, with no autoimmune or treatment-related adverse events of grade 3 or 4, and the results suggest that immune checkpoint blockade is worthy of further study in follicular lymphoma.

TL;DR: Multivariate analysis identified performance status ≥2 and bone marrow involvement as independent adverse prognostic factors for EFS and OS and further research is needed to identify predictive and/or targetable biological markers and novel therapeutic approaches for DHL patients.

TL;DR: The described results are a step forward toward developing a curative strategy for recurrent follicular lymphoma and all 18 patients who were tested and had evidence of JH/bcl-2 fusion transcripts in the bone marrow at study entry experienced continuous molecular remission.

TL;DR: Oral lenalidomide plus rituximab is well tolerated and effective for patients with relapsed or refractory MCL and the primary efficacy endpoint was overall response (complete or partial response).